The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Autolus ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Autolus Therapeutics, a UCL spinout company, has received authorisation from the UK Medicines and Healthcare products ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) ...

Traders use this information to analyze potential trades and assess market sentiment for Autolus Therapeutics. In The Money Expiration Date April 17, 2025 May 16, 2025 June 20, 2025 September 19 ...

CAR T-Cell Therapy Market SizeThe global CAR T-cell therapy market was worth USD 11.11 billion in 2024 and is expected to ...

View the AUTL option chain and compare options of Autolus Therapeutics Ltd stock. Analyze the various options available, including call options (the right to buy) and put options (the right to ...

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"Linda brings more than 20 years of financial, operational and executive leadership success at innovative life science ...

She is currently on the Board of Directors of Arvinas, Autolus Therapeutics and Hemab Therapeutics. “I am thrilled with the opportunity to contribute my skills and experience to a Company at the ...